ClinicalTrials.gg
RecruitingNCT04790305Updated Jun 27, 2024

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

A Phase 4 interventional study of Huaier Granule in Carcinoma Breast, Triple-negative Breast Cancer and Invasive Ductal Carcinoma, Breast, sponsored by Fudan University. Recruiting at 34 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-06-27.

Sponsored by Fudan University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,072
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 260 studies in Breast Neoplasms by Fudan University — 122 open to participants now, 142 under way, 31 of them phase 3. Breast Neoplasms · Fudan University.

Planned enrollment
26th of 199
1,072 · median 170
Started
2021
with 15 others
Phase 4
5 of 260
4 open now
Primary completion
2027-12
later than 86 of 141 live
Registered
99th of 260
by date

Among the 260 studies in Breast Neoplasms by Fudan University, this one is the 26th largest by planned enrollment of the 199 interventional ones that give a count, is one of 16 that started in 2021, is one of 5 in phase 4, reaches primary completion later than 86 of the 141 other live ones, and was the 99th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

122 of the 260 studies in Breast Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

117 more — sign in →

By country, each count listing its studies:

All 122 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Breast Neoplasms by Fudan University, or all of them as a file.
02

Study summary

This is a prospective, multicenter, randomized, parallel controlled, open-label study. The primary purpose of this study is to evaluate the efficacy of Huaier Granule on postoperative adjuvant therapy of high-risk early-stage triple-negative invasive ductal carcinoma. The Secondary purposes are to evaluate the safety of long-term use of Huaier granules as postoperative adjuvant treatment of high-risk early-stage triple-negative invasive ductal carcinoma, and the changes of quality of life score after treatment with Huaier granule.

Read the detailed description

Triple-negative breast cancer(TNBC) accounts for 10% to 20% of breast cancer. TNBC is more likely to show lymph node involvement at diagnosis, and biologically more aggressive. Women with TNBC have a higher rate of distant recurrence at early-stage and a worse 5-year prognosis than women of other molecular types. Although PARP inhibitors and immune checkpoint inhibitors are showing promise to patients with advanced TNBC, however, these targeted therapies and immunotherapy for TNBC can not increase the clinical benefits of early-stage patients.

As adjuvant therapy for hepatocellular carcinoma after curative liver resection, a multicentre study demonstrated a significant prolongation of RFS and reduced extrahepatic recurrence in Huaier group. Retrospective studies have shown that Huaier granules can improve the rates of disease-free survival(DFS) and overall survival(OS), and reduce the incidence of adverse events among operable patients with TNBC.

In this study, 1072 high-risk early-stage triple-negative invasive ductal carcinoma participants (536 cases in the observation group and 536 cases in the control group) from 30 research centers will be included. The block randomization was adopted, participants will be randomly divided into the experimental group (Huaier granule plus conventional treatment/visit) and control group (conventional treatment/visit only). All participants will be followed up for 5 years, including 2-year treatment follow-up and 3-year survival follow-up. During the treatment period, the participants will be followed up every 3 months, and the survival follow-up period will be followed up every 6 months.

03

Conditions studied

  • Carcinoma Breast
  • Triple-negative Breast Cancer
  • Invasive Ductal Carcinoma, Breast

Keywords

  • Huaier Granule
  • Triple-negative Breast Cancer
  • Invasive Ductal Carcinoma, Breast
  • Adjuvant Treatment
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged from 18 to 70.
  2. confirmed as breast invasive ductal carcinoma.
  3. Molecular typing of breast lesions is triple-negative breast cancer, when the patient had multicentric lesions at the same time, all invasive lesions were confirmed as triple-negative.
  4. Regional lymph node confirmed by postoperative pathology [except isolated tumor cells ( ITC )], or tumor response did not achieve pathological complete response (pCR) after therapy [neoadjuvant chemotherapy completed at least four cycles, the breast has residual invasive cancer or axillary lymph node metastasis ( except isolated tumor cells ) .]
  5. There was no local recurrence and distant metastasis of the tumor.
  6. The time of randomization is during the postoperative adjuvant therapy or within 60 days after the end of the last postoperative adjuvant therapy.
  7. performance status (ECOG PS) ≤ 1.
  8. Hepatic function and renal function: serum creatinine level ≤ 1.5 × (ULN), (AST) concentration / alanine aminotransferase (ALT) concentration≤ 2.5 × ULN,total serum concentration≤ 1.5 × ULN.
  9. Blood routine: ≥ 1.5*109 / L, count ≥ 100*109 / L, concentration ≥ 90 g / L (without transfusion).
  10. The participants volunteered to join the study with good compliance and signed an form.

Exclusion criteria

Exclusion Criteria:

  1. Bilateral breast cancer.
  2. Complicated with severe cardiopathy, hepatopathy, nephropathy, endocrine system diseases. According to the researchers' judgement, the comorbidities can cause unacceptable safety risks and affect participants' compliance with research programs.
  3. Suffering from malignant tumors other than breast cancer (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix) in the past 5 years.
  4. Allergic to Huaier granule.
  5. Pregnant or lactating women, and those who planning a pregnancy during the study period.
  6. Participating in other clinical trials or participated in other clinical studies within 3 months.
  7. Patients with a poor compliance, or they are not appropriate for this study because of other reasons considered by the researchers.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,072 participants (estimated)

Study arms

  • Experimental
    Huaier Granule + Conventional Treatment/visit

    Huaier Granule: oral administration, 20g each time, 3 times a day. The starting time of Huaier granule: from the beginning of adjuvant therapy to the end of adjuvant therapy, and within 60 days after the end of adjuvant therapy is also acceptable. Conventional Treatment/visit:The postoperative adjuvant therapy and visit of TNBC are based on clinical routine.

    Drug: Huaier Granule

  • No intervention
    Conventional Treatment/visit

    Conventional Treatment/visit:The postoperative adjuvant therapy and visit of TNBC are based on clinical routine.

Interventions

  • DrugHuaier Extract GranuleStudies of Huaier Extract GranuleHuaier Extract Granule pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The subjects in the experimental group will be treated with Huaier Granule continuously for 2 years or until the disease progressed, intolerable toxicity, withdrawal of informed consent form or died for any reason.

    Also known as: Z20000109(NMPA Approval Number)

06

What researchers measure

Primary outcomes

  1. 3-year rates of disease-free survival

    Disease-free survival (DFS):The time from randomization until the date of the first occurrence of one of the following events: recurrence of ipsilateral invasive breast tumor, local recurrence, distant metastasis, death from any cause, contralateral invasive breast cancer, ipsilateral ductal carcinoma in situ, contralateral ductal carcinoma in situ, second primary invasive carcinoma (except breast cancer). 3-year rates of disease-free survival: The percentage of participants who have not occurred events described in the DFS definition within 3 years.

    Time frame: Start of treatment until 3-year follow-up

Secondary outcomes

  1. 3-year rates of overall survival

    Overall survival (OS): The time from randomization until the date of death from any cause. 3-year rates of overall survival: The percentage of participants who have not died from any cause within 3 years.

    Time frame: Start of treatment until 3-year follow-up

  2. 3-year rates of invasive-disease-free survival

    Invasive-disease-free survival (iDFS): The time from randomization until the date of the first occurrence of one of the following events: recurrence of ipsilateral invasive breast tumor, local recurrence, distant metastasis, death from any cause, contralateral invasive breast cancer, second primary invasive carcinoma (except breast cancer). 3-year rates of invasive-disease-free survival: The percentage of participants who have not occurred events described in the iDFS definition within 3 years.

    Time frame: Start of treatment until 3-year follow-up

  3. 5-year rates of disease-free survival

    5-year rates of disease-free survival: The percentage of participants who have not occurred events described in the DFS definition within 5 years.

    Time frame: Start of treatment until 5-year follow-up

  4. 5-year rates of overall survival

    5-year rates of overall survival: The percentage of participants who have not died from any cause within 5 years.

    Time frame: Start of treatment until 5-year follow-up

  5. 5-year rates of invasive-disease-free survival

    5-year rates of invasive-disease-free survival: The percentage of participants who have not occurred events described in the iDFS definition within 5 years.

    Time frame: Start of treatment until 5-year follow-up

  6. Changes in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire

    Quality of Life (QOL) will be measured by European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30). The scope of each domain is 0 to 100. Higher scores in the functional and general health areas indicate better functional status and quality of life, and higher scores in the symptomatic areas indicate more symptoms or problems (poorer quality of life).

    Time frame: Up to 5 years since the start of treatment

  7. Incidence and severity of AE or SAE

    AE: Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAE: A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.

    Time frame: Start of treatment until 3 year after enrollment

  8. Incidence and severity of ADR,SUSAR or SADR

    All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions. A SADR is a serious ADR according to the above criteria of SAE. A SUSAR is an unexpected SADR.

    Time frame: Start of treatment until 3 year after enrollment

07

Study locations

34 of 34 sites recruiting
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
    Recruiting
    • Jingjie Zhang · Contact
  • The First Affiliated Hospital of USTC, Anhui Provincial Hospital
    Hefei, Anhui, China
    Recruiting
    • Xiaopeng Ma · Contact
  • Cancer Hospital Chinese Academy of Medical Science
    Beijing, Beijing, China
    Recruiting
    • Xiang Wang · Contact
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
    Recruiting
    • Guobing Yin · Contact
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
    Recruiting
    • Xia Chen · Contact
  • Guangdong Provincial Hospital of Traditional Chinese Medicine
    Guangzhou, Guangdong, China
    Recruiting
    • Qianjun Chen · Contact
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong, China
    Recruiting
    • Kun Wang · Contact
  • The Fourth Hospital of Hebei Medical University, Hebei Tumor Hospital
    Shijia Zhuang, Hebei, China
    Recruiting
    • Cuizhi Geng · Contact
  • The First Affiliates Hospital of Ha'erbin University
    Ha'erbin, Heilongjiang, China
    Recruiting
    • Yi Zhou · Contact
  • Henan Provincial People's Hospital
    Zhengzhou, Henan, China
    Recruiting
    • Hui Liu · Contact
  • Hubei Cancer Hospital
    Wuhan, Hubei, China
    Recruiting
    • Yaojun Feng · Contact
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei, China
    Recruiting
    • Yi Tu · Contact
  • Tongji Medical College of HUST
    Wuhan, Hubei, China
    Recruiting
    • Xingrui Li · Contact
  • Union Hospital Tongji Medical College Huazhong Univeristy of Science and Technology
    Wuhan, Hubei, China
    Recruiting
    • Tao Huang · Contact
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei, China
    Recruiting
    • Gaosong Wu · Contact
  • Hunan Cancer Hospital
    Changsha, Hunan, China
    Recruiting
    • Dongfang Li · Contact
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan, China
    Recruiting
    • Enxiang Zhou · Contact
  • Jiangsu Province Hospital of Chinese Medicine
    Nanjing, Jiangsu, China
    Recruiting
    • Chang Yao · Contact
  • Jiangsu Provincial Hospital
    Nanjing, Jiangsu, China
    Recruiting
    • Shui Wang · Contact
  • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
    Nanjing, Jiangsu, China
    Recruiting
    • Yongzhong Yao · Contact
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
    Recruiting
    • Jianxia Liu · Contact
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu, China
    Recruiting
    • Deyuan Fu · Contact
  • The Second Hospital of Jilin University
    Chang chun, Jilin, China
    Recruiting
    • Yan Zhang · Contact
  • Liaoning Cancer Hospital & Institute
    Shenyang, Liaoning, China
    Recruiting
    • Daqing Jiang · Contact
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
    Recruiting
    • Qifeng Yang · Contact
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
    Recruiting
    • Haibo Wang · Contact
  • LongHua Hospital Shanghai University of Traditional Chinese Medicine
    Shanghai, Shanghai, China
    Recruiting
    • Sheng Liu · Contact
  • The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)
    Xi'an, Shanxi, China
    Recruiting
    • Shuqun Zhang · Contact
  • The First Affiliatied Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
    • Peifen Fu · Contact
  • The Second Affiliated Hospital Zhejiang Univerisity of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
    • Yiding Chen · Contact
  • Huamei Hospital, University of Chinese Academy of Sciences
    Ningbo, Zhejiang, China
    Recruiting
    • Xujun Li · Contact
  • Ningbo Medical Center Lihuili Hospital
    Ningbo, Zhejiang, China
    Recruiting
    • Weizhu Wu · Contact
  • The First School of Medicine, School of Information and Engineering,the First Affiliated Hospital of WMU
    Wenzhou, Zhejiang, China
    Recruiting
    • Ouchen Wang · Contact
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Dec 2027, 78 months after the start.

Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 78 months is above that.

Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2021
First posted
Mar 10, 2021
StartActual
Jun 18, 2021
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jul 28, 2028
Last update
Jun 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04790305
Lead sponsor
Fudan University
Collaborators
LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology
Responsible party
Zhimin Shao (Professor, Fudan University) — Principal investigator
First posted
Mar 10, 2021
Start date
Jun 18, 2021
Primary completion
Dec 31, 2027 (estimated)
Completion
Jul 28, 2028 (estimated)
Last update
Jun 27, 2024

Study contacts

Zhimin Shao, PhD
Contact
zhimingshao@yahoo.com
+86-18017312288
Liang Huang, PhD
Contact
fdhlyx@163.com
+86-18121299334
Zhimin Shao, PhD
principal investigator · Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Huaier Extract Granule

Start the discussion